Published in Biopharm Drug Dispos on June 27, 2014
Age-structured population model of cell survival. J Pharmacokinet Pharmacodyn (2017) 0.75
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res (2005) 1.96
Primary breast lymphoma - a review of the literature and report of three cases. Arch Med Sci (2011) 1.43
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn (2009) 1.33
Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J (2010) 1.22
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J (2010) 1.10
Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn (2007) 1.08
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther (2006) 1.06
Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J (2007) 1.03
Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin Pharmacokinet (2008) 1.02
Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn (2012) 1.01
Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol (2008) 1.00
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol (2010) 0.99
Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn (2004) 0.96
Modulation of the activity of calcium-activated neutral proteases (calpains) in chronic lymphocytic leukemia (B-CLL) cells. Blood (2002) 0.93
Prediction of peptide retention at different HPLC conditions from multiple linear regression models. J Proteome Res (2005) 0.93
Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol (2007) 0.93
Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet (2009) 0.92
Comparative characteristics of HPLC columns based on quantitative structure-retention relationships (QSRR) and hydrophobic-subtraction model. J Chromatogr A (2005) 0.91
Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn (2009) 0.91
Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn (2005) 0.91
Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. J Pharmacol Exp Ther (2010) 0.90
Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats. Cytometry A (2009) 0.90
Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol (2007) 0.90
Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients. Eur J Gastroenterol Hepatol (2003) 0.90
Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn (2006) 0.89
Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci (2004) 0.89
Reversed-phase TLC and HPLC retention data in correlation studies with in silico molecular descriptors and druglikeness properties of newly synthesized anticonvulsant succinimide derivatives. Mol Pharm (2011) 0.89
A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol (2011) 0.88
Flow cytometric assessment of homeostatic aging of reticulocytes in rats. Exp Hematol (2008) 0.88
Multiple sclerosis-associated virus-related pol sequences found both in multiple sclerosis and healthy donors are more frequently expressed in multiple sclerosis patients. J Neurovirol (2003) 0.88
Comparative proteome analysis of acute myeloid leukemia with and without maturation. J Proteomics (2012) 0.87
Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma. Ann Hematol (2007) 0.87
Simultaneous determination of pKa and lipophilicity by gradient RP HPLC. Anal Chem (2006) 0.87
Predictions of peptides' retention times in reversed-phase liquid chromatography as a new supportive tool to improve protein identification in proteomics. Proteomics (2009) 0.86
Determination of pKa by pH gradient reversed-phase HPLC. Anal Chem (2004) 0.86
Electrochemical impedance spectroscopy for study of amyloid beta-peptide interactions with (-) nicotine ditartrate and (-) cotinine. Biosens Bioelectron (2006) 0.86
Evaluation and comparison of random amplification of polymorphic DNA, pulsed-field gel electrophoresis and ADSRRS-fingerprinting for typing Serratia marcescens outbreaks. FEMS Immunol Med Microbiol (2003) 0.86
Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. J Appl Genet (2008) 0.85
Evaluation of a novel method based on amplification of DNA fragments surrounding rare restriction sites (ADSRRS fingerprinting) for typing strains of vancomycin-resistant Enterococcus faecium. J Microbiol Methods (2003) 0.85
Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model. Cytometry A (2007) 0.85
Comparative evaluation of high-performance liquid chromatography stationary phases used for the separation of peptides in terms of quantitative structure-retention relationships. J Chromatogr A (2007) 0.85
MSRV pol sequence copy number as a potential marker of multiple sclerosis. Pol J Pharmacol (2004) 0.84
Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. Clin Pharmacokinet (2013) 0.84
Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy. Jpn J Infect Dis (2007) 0.84
A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats. J Pharm Sci (2002) 0.84
Amplification of hTERT and hTERC genes in leukemic cells with high expression and activity of telomerase. Oncol Rep (2006) 0.84
The state-of-the-art determination of urinary nucleosides using chromatographic techniques "hyphenated" with advanced bioinformatic methods. Anal Bioanal Chem (2011) 0.83
Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn (2006) 0.83
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit (2005) 0.83
Liquid chromatography tandem mass spectrometry study of urinary nucleosides as potential cancer markers. J Chromatogr A (2013) 0.83
Artificial neural network analysis for evaluation of peptide MS/MS spectra in proteomics. Anal Chem (2004) 0.83
Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J (2014) 0.82
The application of gradient reversed-phase high-performance liquid chromatography to the pK(a) and log k(w) determination of polyprotic analytes. J Chromatogr A (2008) 0.82
Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet (2009) 0.82
Chromatographic retention parameters in medicinal chemistry and molecular pharmacology. Curr Med Chem (2003) 0.82
Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. J Clin Pharmacol (2011) 0.82
Quantitative structure-retention relationships in affinity high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.81
Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. Pharmacol Rep (2012) 0.81
Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls. Gynecol Endocrinol (2010) 0.81
Transmigration of blood leukocytes into the peritoneal cavity is related to the upregulation of ICAM-1 (CD54) and Mac-1 (CD11b/CD18) adhesion molecules. Perit Dial Int (2004) 0.80
pH/organic solvent double-gradient reversed-phase HPLC. Anal Chem (2005) 0.80
Development and validation of urinary nucleosides and creatinine assay by capillary electrophoresis with solid phase extraction. J Pharm Biomed Anal (2007) 0.80
Genetic investigation of biological materials from patients after stem cell transplantation based on autosomal as well as Y-chromosomal markers. Int J Legal Med (2012) 0.80
D-optimal designs for parameter estimation for indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn (2009) 0.80
Association constants of pyridine and piperidine alkaloids to amyloid beta peptide determined by electrochemical impedance spectroscopy. Curr Alzheimer Res (2010) 0.80
New supervised alignment method as a preprocessing tool for chromatographic data in metabolomic studies. J Chromatogr A (2012) 0.79
Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid. AAPS J (2011) 0.79
Metabolomic approach for determination of urinary nucleosides as potential tumor markers using electromigration techniques. Electrophoresis (2010) 0.79
Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms. Acta Haematol (2014) 0.79
Predictive approaches to gradient retention based on analyte structural descriptors from calculation chemistry. J Chromatogr A (2003) 0.79
Cancer procoagulant in patients with adenocarcinomas. Blood Coagul Fibrinolysis (2005) 0.79
Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis. J Pharm Biomed Anal (2010) 0.79
Micellar liquid chromatography for lipophilicity determination of new biologically active 1,3-purinodiones. J Sep Sci (2010) 0.79
Correctness of protein identifications of Bacillus subtilis proteome with the indication on potential false positive peptides supported by predictions of their retention times. J Biomed Biotechnol (2009) 0.78
pH gradient reversed-phase liquid chromatography as a fractionation tool for the separation of peptides. Talanta (2007) 0.78
Combination of linear solvent strength model and quantitative structure-retention relationships as a comprehensive procedure of approximate prediction of retention in gradient liquid chromatography. J Chromatogr A (2002) 0.78
Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children. Pharmacol Rep (2013) 0.78
Efficient recovery of electrophoretic profiles of nucleoside metabolites from urine samples by multivariate curve resolution. Electrophoresis (2009) 0.78
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol (2006) 0.78
Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. J Pharm Sci (2003) 0.78
Quantitative structure-retention relationships models for prediction of high performance liquid chromatography retention time of small molecules: endogenous metabolites and banned compounds. Anal Chim Acta (2013) 0.78
Verification of the exponential model of body temperature decrease after death in pigs. Exp Physiol (2005) 0.77
Solving delay differential equations in S-ADAPT by method of steps. Comput Methods Programs Biomed (2013) 0.77
Comparative proteomics in acute myeloid leukemia. Contemp Oncol (Pozn) (2012) 0.77
Chromatographic retention parameters in correlation analysis with in silico biological descriptors of a novel series of N-phenyl-3-methyl succinimide derivatives. J Pharm Biomed Anal (2012) 0.77
Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. Am J Hypertens (2013) 0.77
Evaluation of a generalized use of the log Sum(k+1)AA descriptor in a QSRR model to predict peptide retention on RPLC systems. J Sep Sci (2009) 0.77
Lack of correlation between telomere length and telomerase activity and expression in leukemic cells. Int J Mol Med (2003) 0.77
Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J Pharmacokinet Pharmacodyn (2012) 0.77
Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. J Clin Pharmacol (2002) 0.77
Comparison of RP-HPLC columns used for determination of nucleoside metabolic patterns in urine of cancer patients. Bioanalysis (2012) 0.77
Evaluation of the silanol-suppressing potency of ionic liquids. J Sep Sci (2006) 0.77
Influence of haloperidol and clozapine on some behavioral effects in rats. Arzneimittelforschung (2006) 0.77
Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies. AAPS J (2014) 0.77
Mydriasis model in rats as a simple system to evaluate α2-adrenergic activity of the imidazol(in)e compounds. Pharmacol Rep (2013) 0.76
The application of 19F magnetic resonance ex vivo imaging of three-dimensional cultured breast cancer cells to study the effect of delta-tocopherol. Anal Biochem (2009) 0.76
[Recent indications for home oxygen therapy]. Pol Merkur Lekarski (2011) 0.76